CN101829185B - Medicinal composition for resisting influenza virus - Google Patents
Medicinal composition for resisting influenza virus Download PDFInfo
- Publication number
- CN101829185B CN101829185B CN2010101971283A CN201010197128A CN101829185B CN 101829185 B CN101829185 B CN 101829185B CN 2010101971283 A CN2010101971283 A CN 2010101971283A CN 201010197128 A CN201010197128 A CN 201010197128A CN 101829185 B CN101829185 B CN 101829185B
- Authority
- CN
- China
- Prior art keywords
- herba
- pharmaceutical composition
- influenza virus
- weight portion
- radix glycyrrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition for resisting influenza virus, which consists of the following three medicaments in part by weight: 1 to 80 parts of artemisia rupestris, 1 to 30 parts of artemisia annua and 1 to 30 parts of liquoric root. The medicinal composition has the advantages of low drug resistance, small side effect, less adverse reaction and the like, has the comprehensive effects of restraining the virus replication, adjusting the immunity, improving the blood circulation, relieving heat and pain, resisting bacteria and diminishing inflammation and the like, and has the unique advantage and the wide development prospect in the aspect of preventing and treating the influenza virus.
Description
Technical field
The present invention relates to Chinese medicine composition, especially a kind of pharmaceutical composition of resisiting influenza virus.
Background technology
Influenza is called for short influenza, is a kind of acute respiratory infectious disease that is caused by influenza virus.Because the antigenic variation ability of influenza virus is strong; The difference of individual immunity power in addition, the protective rate of vaccine is not high, moreover; Vaccine only has preventive effect to known influenza virus sub-strain, and invalid for the new type influenza virus that is produced by antigenic drift or antigenicity conversion.Other chemicals tackle this primary or with the anthropogeny since aspect the microorganism that just symbiosis is deposited with it, also show slightly powerless.
Think that medically the Influenza Virus Orthomyxoviridae is one type of RNA viruses that mucin is had special affinity.Be divided into two types of internal antigens and outer antigens according to position, virus antigen place difference: the core of internal antigens is a singlestranded RNA albumen; Outer antigen is glycoprotein, comprise hemagglutinin (Hemagglutinin, H) and neuraminidase (Neuramindase, N).Different according to its antigenic property, influenza virus is divided into first (A), second (B), third (C) type; Again its virus is divided into some hypotypes (H1～H15, N1～N9).Type B and C type influenza antigen property are more stable, and the A type is to cause popular main pathogen, and its viral surface antigen HA and NA are prone to morph.At present; The Western medicine of prevention and treatment influenza mainly contains M2 inhibitors of ion channels, NA inhibitor and influenza vaccines; Preceding two kinds of drug side effectes are big relatively; And along with the extensively easy generation drug resistance of using, and vaccine only has preventive effect to known influenza virus sub-strain, and is invalid for the new type influenza virus that is produced by antigenic drift or antigenicity conversion.
As, the medicine that is mainly used in the treatment influenza at present is amantadine and rimantadine, two medicines have inhibitory action to A type influenza virus, but invalid to the Type B influenza, and exist certain untoward reaction.Influenza new drug neuraminidase inhibitor such as zanamivir (zanamivir) can suppress duplicating of influenza virus A and B; Be mainly used in the early treatment of influenza; But this medicine is not suitable for the child, the patient that asthma or chronic obstructive pulmonary disease are arranged is had the danger that increases bronchospasm.The Western medicine Oseltamivir uses as a line antiviral drugs, but the scientist of Britain, Denmark, Japan finds successively that the part influenza virus has produced the drug resistance to Oseltamivir.Oseltamivir is as a kind of antiviral drugs, and the case that can only be used for having made a definite diagnosis can not be as preventive usage.
Influenza is called " influenza " in Chinese medicine, belong to epidemic disease class (being infectious disease), and motherland's medical science is thought human feeling's ailment said due to cold or exposure (cause of disease) invasion and attack, and immunity of organisms is low, be not enough to anti-evil and cause a disease, especially when abrupt change of climate, tremble with fear and warm up when not normal more susceptible disease.The basic role mechanism of Chinese medicine resisiting influenza virus is strengthening vital QI to eliminate pathogenic factors or eliminating pathogenic factor for supporting vital QI; Characteristics with integrally-regulated many target treatments; The antiinflammatory antiviral of can not only bringing down a fever; And have an effect that improves the human immunologic function, and, alleviate upper airway symptoms and have more advantage than the antiinflammatory of bringing down a fever of single antiviral treatment.But the one-tenth side's Chinese medicine preparation that also occurs the ability resisiting influenza virus in the market.
Summary of the invention
The present invention is directed to deficiency, propose a kind of pharmaceutical composition of resisiting influenza virus, can effectively prevent and treat the flu that causes by influenza virus, and promptly can be made into various dosage forms through the direct or indirect acceptable accessories that adds of conventional processing.
In order to realize the foregoing invention purpose, the present invention provides following technical scheme: a kind of pharmaceutical composition of resisiting influenza virus comprises the composition of following weight portion:
Herba Achilleae 1～80
Herba Artemisiae annuae 1～30
Radix Glycyrrhizae 1～30.
Preferably, the weight portion of said Herba Achilleae is 10～60.
Preferably, the weight portion of said Herba Artemisiae annuae is 8～20.
Preferably, the weight portion of said Radix Glycyrrhizae is 8～20.
Preferably, this pharmaceutical composition comprises that also weight portion is one or more in 1～50 part Herba Menthae, the Radix Astragali and the Fructus Forsythiae.
Preferably, the weight portion of said Herba Menthae, the Radix Astragali and Fructus Forsythiae is 10～30.
Preferably, the weight portion of each composition is respectively as follows:
Herba Achilleae 10～60
Herba Artemisiae annuae 8～20
Radix Glycyrrhizae 8～20.
Take by weighing mentioned component in proportion, mixing gets final product.Also can be through conventional operational means; In pharmaceutical composition, directly or indirectly add acceptable accessories and promptly can be made into various dosage forms, as: capsule, granule, pill, powder, tablet, oral liquid, syrup, oral cavity disintegration tablet, gargarism, drop pill.
Herba Achilleae
Herba Achilleae is the Compositae herbaceos perennial, is distributed widely in Tianshan Mountains, Altai Mountains.The Herba Achilleae herb contains aminoacid, flavonoid, micro-alkaloid and a small amount of volatile oil; Have effects such as the low detoxifcation of toxicity, antiallergic, tranquillizing and allaying excitement, heat clearing and inflammation relieving.Among the people for a long time medicinal in Xinjiang.Just spreading the proverb among the people of " family have Herba Achilleae not to be afraid of sting, family has Herba Achilleae all kinds of diseases and ailments all to remove " by Serpentis from ancient times.Record in Qing Dynasty's pharmacy man's supplementary Amplifications of the Compendium of Materia Medica that ZHAO Xue-Min is collected (1765): " Barkol goes out a kind of medicine, the name Herba Achilleae.Give birth in the remote mountains and do not have branch and leaf, the soil of growing sturdily, abnormal smells from the patient such as an Artemisia.Between April, herd horses into the mountain, receive grass and take and return, soft extracts to be to sell the guest from afar, have the dealer to Lanzhou the goods seller.Promoting blood circulation and detoxication goes all stagnant, diseases such as severe and lingering illness or habit YIN-cold ".
Nature and flavor: cold, acrid in the mouth, hardship;
Effect: heat clearing away, anti-inflammatory analgetic, removing pathogenic heat from blood and toxic substance from the body;
Function cures mainly: expelling pathogenic wind from the body surface; Removing food stagnancy is good for the stomach; Promoting blood circulation to remove blood stasis.The cold flu of main air; Stagnation of QI due to dyspepsia; Abdominal distention; The traumatic injury congestive edema; Rubella; Snakebite.
Relevant Pharmacological action study data shows that Herba Achilleae has effects such as antibacterium, antiviral, malaria, anthelmintic, function of gallbladder promoting, heart tonifying, detoxifcation, hemostasis, expansion bronchus, antitumor, antiallergic and enhance immunity function.
Herba Artemisiae annuae
Be the herb of feverfew Herba Artemisiae annuae, be about 60～100 centimetres.Stem is cylindrical, and surperficial light brown or taupe brown have vertical crest line, and matter is hard, and fracture is coarse, the marrow of central adularescent.The most blades of twig tool, matter is crisp, is prone to cracked.The branch of band fruit ear or inflorescence, how blade comes off, the xanchromatic bract of the only remaining coccoid palm fibre of inflorescence, like roe, matter is crisp frangible.Special fragrance is arranged, and bitter in the mouth has refrigerant sense.Green with yellow skin, gas is fragrant, the free from admixture person is good.Whole nation most of areas has product.All make Herba Artemisiae Annuae at present uses in national the greater part.
Meridian distribution of property and flavor: arduous, cold, nontoxic.Go into the heart, lung, liver three warps.
Effect cures mainly: heat clearing away, expelling summer-heat removes and steams.Control epidemic febrile disease, summer-heat, hectic fever due to YIN-deficiency consumptive fever, malaria, dysentery, jaundice, scabies, pruritus.
Pharmacological action:
1, malaria effect;
2, antibacterial action;
3, parasiticide effect;
4, refrigeration function;
5, regulate immunization.
Radix Glycyrrhizae
Property is put down, and sweet in the mouth is returned 12 warps.On the traditional Chinese medical science, the Radix Glycyrrhizae invigorating the spleen and replenishing QI is grown and to be coughed lung moistening, and the emergency detoxifcation is in harmonious proportion hundred medicines.Radix Glycyrrhizae is used as medicine with a long history.Before two thousand years, Shennong's Herbal is just classified it on medicine as and is taken advantage of.The physician of Southern Dynasties TAO Hong-Jing is " state is old " with the Radix Glycyrrhizae honor, and speech: " king of the most medicines of this grass, classical prescription is rare without the person." " state is old ", i.e. Supreme Being teacher's title.Praise highly Radix Glycyrrhizae and be medicine it " Supreme Being teacher ", its reason is released in Compendium of Material Medica as Li Shizhen (1518-1593 A.D.): " Radix Glycyrrhizae be monarch in all medicines, controls 72 kinds of mammary calculus poison, and it is malicious to separate 1,002 BAICAO wood, and many medicines that are in harmonious proportion are gained merit, thus have ' state is old ' number.”
The effect of Radix Glycyrrhizae:
(1) adrenocortical hormone appearance effect
Radix Glycyrrhizae extractum, glycyrrhizin, enoxolone all have the effect of desoxycortone appearance to multiple animal, can promote sodium, water retention, and row's potassium increases, and show the effect of mineralocorticoid appearance; Radix Glycyrrhizae extractum, glycyrrhizin can make that rat chest gland atrophy, adrenal gland's weight increase, eosinophil leucocyte and lymphopenia, the release 17-hydroxycorticosterone in urine middle reaches increase in the blood, show the effect of glucocorticoid appearance.
(2) regulate body's immunity
Radix Glycyrrhizae has the heterogeneity that strengthens and suppress body's immunity.
(3) antibiotic, antiviral, antiinflammatory, antiallergic action
Liquorice flavonoids compound has inhibitory action to staphylococcus aureus, bacillus subtilis, yeast, fungus, streptococcus etc.Glycyrrhizin to human immunity property defective virus (HIV, HIV), hepatitis virus, vesicle property oral cavity virus, adenovirus III type, herpes simplex virus I-type, vaccinia virus etc. all have the obvious suppression effect.Radix Glycyrrhizae has 17-hydroxy-11-dehydrocorticosterone appearance antiinflammatory action, to mice chemical auricle edema, abdominal cavity capillary permeability increase, rat granuloma is swollen, formaldehyde property rat paw edema, chondrus ocellatus Holmes colloidality rat arthritis etc. all have inhibitory action.
Herba Menthae
Herba Menthae for labiate " Herba Menthae " promptly belongs to other dry herbs together, is born in by the hill wetland river more, and rhizome grows wild underground.The blue or green gas fragrance of Herb.Leaf is spent little lavender to life, and lip is spent the dark violet brown granule fruit of back knot.Herba Menthae is one of Chinese conventional Chinese medicine.It is hot cold property sweating and heat resolving medicine, and is effective to treatment influenza, headache, conjunctival congestion, fever of the body, throat, dental bed disease such as swell and ache.But effect training the mind dysmenorrhoea, skin pruritus, erythra and eczema etc. in prescription.
The Radix Astragali
The Radix Astragali comprises the plant Radix Astragali and the Chinese crude drug Radix Astragali.Here be meant the Chinese crude drug Radix Astragali, the Chinese crude drug Radix Astragali is the root of leguminous herbaceous plant's Radix Astagali, Radix Astragali, has effects such as invigorating QI to consolidate the body surface resistance, diuretic detumescent, expelling pus and toxin by strengthening QI, granulation promoting.The medicinal history in existing more than 2000 year so far of the Radix Astragali, modern study, the Radix Astragali contain various trace elements such as Saponin, sucrose, polysaccharide, several amino acids, folic acid and selenium, zinc, copper.The enhancing human body immunity function arranged, protect the liver, diuresis, defying age, anti-stress, blood pressure lowering and antibacterial action more widely.But the table excess pathogen is contained, retention of dampness due to stagnation of QI, food stagnation is stagnated, carbuncle from the beginning of or excess syndrome such as the back pyretic toxicity Shang Sheng that bursts, and hyperactivity of YANG due to deficiency of YIN person must prohibit clothes.
Fructus Forsythiae
Pharmacological actions such as that Fructus Forsythiae has is antibiotic, heart tonifying, diuresis, town are told, diseases such as the acute anemopyretic cold of forsythia fruit for treating commonly used, carbuncle sore tumefacting virus, tuberculous lymphadenitis, urinary tract infection cure mainly: Chinese medicine is controlled calentura from the beginning of, anemopyretic cold; Heating, vexed, laryngopharynx swelling and pain; Macule, erysipelas, scrofula; The carbuncle pyogenic infections from tumour or sore, acute nephritis, pyretic stranguria.The mongolian medicine subcutaneous ulcer of harnessing the Yellow River, intestinal twinge, " association day " disease, intestinal heat.
Compared with prior art; Pharmaceutical composition of the present invention is made up of Herba Achilleae, Herba Artemisiae annuae and three kinds of medicines of Radix Glycyrrhizae; Advantage such as have not only that drug resistance is low, side effect and untoward reaction are few; And suppress virus replication in addition, regulate immunologic function, improve blood circulation, antipyretic-antalgic, and comprehensive effect such as anti-inflammation, it has special advantages and vast potential for future development aspect control influenza virus.
The specific embodiment
A kind of pharmaceutical composition of resisiting influenza virus comprises the composition of following weight portion:
Herba Achilleae 1～80
Herba Artemisiae annuae 1～30
Radix Glycyrrhizae 1～30.
Aforementioned pharmaceutical compositions is made up of Herba Achilleae, Herba Artemisiae annuae and three kinds of medicines of Radix Glycyrrhizae; Advantage such as have not only that drug resistance is low, side effect and untoward reaction are few; And suppress virus replication in addition, regulate immunologic function, improve blood circulation, antipyretic-antalgic, and comprehensive effect such as anti-inflammation, it has special advantages and vast potential for future development aspect control influenza virus.
Describe the present invention below in conjunction with specific embodiment, the description of this part only is exemplary and explanatory, should any restriction not arranged to protection scope of the present invention.
Embodiment 1
A kind of water decoction of pharmaceutical composition of resisiting influenza virus, carry out routine by the raw material of following weight portion and decoct and obtain:
Herba Achilleae 30
Herba Artemisiae annuae 12
Radix Glycyrrhizae 12.
Embodiment 2
A kind of capsule of pharmaceutical composition of resisiting influenza virus obtains by adding conventional adjuvant in the raw material powder of following weight portion:
Herba Achilleae 1
Herba Artemisiae annuae 30
Radix Glycyrrhizae 1.
Embodiment 3
A kind of granule of pharmaceutical composition of resisiting influenza virus obtains by adding conventional adjuvant granulation in the raw material powder of following weight portion:
Herba Achilleae 80
Herba Artemisiae annuae 1
Radix Glycyrrhizae 30.
Embodiment 4
A kind of pill of pharmaceutical composition of resisiting influenza virus obtains by adding conventional adjuvant pill in the raw material powder of following weight portion:
Herba Achilleae 10
Herba Artemisiae annuae 20
Radix Glycyrrhizae 8
Herba Menthae 50.
Embodiment 5
A kind of powder of pharmaceutical composition of resisiting influenza virus, ground by the raw material of following weight portion and to obtain:
Herba Achilleae 60
Herba Artemisiae annuae 3
Radix Glycyrrhizae 10
The Radix Astragali 1.
Embodiment 6
A kind of tablet of pharmaceutical composition of resisiting influenza virus obtains by adding conventional adjuvant film-making in the raw material powder of following weight portion:
Herba Achilleae 3
Herba Artemisiae annuae 10
Radix Glycyrrhizae 20
Fructus Forsythiae 26.
Embodiment 7
A kind of syrup of pharmaceutical composition of resisiting influenza virus carries out routine by the raw material of following weight portion and decocts, and adds sweeting agent then and obtains:
Herba Achilleae 30
Herba Artemisiae annuae 13
Radix Glycyrrhizae 15
The Radix Astragali 10
Fructus Forsythiae 20.
Embodiment 8
A kind of oral cavity disintegration tablet of pharmaceutical composition of resisiting influenza virus adds conventional adjuvant by the raw material of following weight portion and obtains:
Herba Achilleae 68
Herba Artemisiae annuae 30
Radix Glycyrrhizae 30
Herba Menthae 30
The Radix Astragali 5
Fructus Forsythiae 12.
Embodiment 9
A kind of gargarism of pharmaceutical composition of resisiting influenza virus after the raw material process decoction by following weight portion, is diluted to suitable concn and obtains:
Herba Achilleae 10
Herba Artemisiae annuae 20
Radix Glycyrrhizae 20
Herba Menthae 8
The Radix Astragali 10.
Embodiment 10
A kind of drop pill of pharmaceutical composition of resisiting influenza virus carries out routine by the raw material of following weight portion and decocts, and fill becomes drop pill to obtain then:
Herba Achilleae 18
Herba Artemisiae annuae 14
Radix Glycyrrhizae 14
Herba Menthae 30
Fructus Forsythiae 10.
The clinical trial example
Adopt the product of the foregoing description 1 to 10 resulting various dosage forms,, carry out clinical observation on the therapeutic effect to suffering from the influenza patient.
Method:
Treatment group: oral each embodiment medicament, every day 3 times.
Matched group: oral ribavirin granule 0.15g, 1 day 3 times.
The curative effect of two groups of cases relatively
The result: above-mentioned traditional Chinese medicine composition for treating influenza curative effect obviously is superior to matched group.Therefore; Preparation popularity flu of the present invention, upper respiratory tract infection determined curative effect; Characteristics with integrally-regulated many target treatments, the antiinflammatory antiviral of can not only bringing down a fever, and have the effect that improves the human immunologic function; And, alleviate upper airway symptoms and have more advantage than the antiinflammatory of bringing down a fever of single antiviral treatment.
The antiviral experiment
1 experiment grouping experiment is established viral infection matched group, ribavirin injection matched group and drug group, the pharmaceutical composition that drug group adopts the foregoing description 1 to 10 to obtain, and each embodiment establishes 3 experimental concentrations: high dose group (600 μ g.ml
-1), middle dose groups (300 μ g.ml
-1) and low dose group (100 μ g.ml
-1); Each concentration is divided into 3 kinds of dosing methods again: 1. add medicine postoperative infection virus group earlier: cultured cell washes out after adding medicine cultivation 2h earlier, washes out behind the viral adsorption 2h, changes drug again and keeps the liquid group.2. add medicine infective virus group simultaneously: virus inoculation adds medicine simultaneously, washes out behind the 2h, changes drug again and keeps the liquid group; 3. add drug group behind the first infective virus: with washing out behind the virus absorption 2h, add drug group more earlier;
The antiviral experiment treats that by above-mentioned group technology permissive cell forms monolayer, inclines and falls culture fluid; Select 3 concentration of 2 times of maximal non-toxic concentration liquids dilution for use, add 96 well culture plates respectively and do not infect in the cell hole with infective virus, change to medicine with concentration at different time; After the cultivation; Microscopically observation of cell pathological changes (CPE), treat that the CPE that the viral infection matched group produces does ++ ++ the time, record cytopathy degree and mtt assay are measured the cell survival amount.
2 results
Medicine antivirus test presentation of results:
*P＜0.05 compares with the ribavirin matched group, and significant difference is arranged;
#P＜0.05 compares with the viral infection matched group, and significant difference is arranged.
In the monolayer HeLa cell that infects 100TCID50RSV; In the high dose group under the dosing method, middle dose groups, the low dose group, the survival volume of cell all is higher than ribavirin matched group (P＜0.05) again for high dose group under 3 kinds of dosing methods and first infective virus; The cell survival amount of all groups all is higher than the viral infection matched group.
The mdck cell survival volume and the ribavirin matched group comparing difference of high, middle dose groups infection H1N1 virus do not have significance (P＞0.05) under 3 kinds of dosing methods.But all be higher than the viral infection matched group.
See that from administering mode 3 kinds of administering modes and virus control group comparing difference all have significance (P＜0.05).Explain that Chinese medicine composition of the present invention has tangible antivirus action.
It below only is preferred implementation of the present invention; Should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the principle of the invention; Can also make some improvement and retouching, these improvement and retouching also should be regarded as protection scope of the present invention.
Claims (8)
1. the pharmaceutical composition of a resisiting influenza virus comprises the composition of following weight portion:
Herba Achilleae 1～80
Herba Artemisiae annuae 1～30
Radix Glycyrrhizae 1～30.
2. pharmaceutical composition according to claim 1 is characterized in that: the weight portion of said Herba Achilleae is 10～60.
3. pharmaceutical composition according to claim 1 is characterized in that: the weight portion of said Herba Artemisiae annuae is 8～20.
4. pharmaceutical composition according to claim 1 is characterized in that: the weight portion of said Radix Glycyrrhizae is 8～20.
5. according to claim 1,2,3 or 4 described pharmaceutical compositions, it is characterized in that: this pharmaceutical composition comprises that also weight portion is one or more in 1～50 part Herba Menthae, the Radix Astragali and the Fructus Forsythiae.
6. pharmaceutical composition according to claim 5 is characterized in that: the weight portion of said Herba Menthae, the Radix Astragali and Fructus Forsythiae is 10～30.
7. pharmaceutical composition according to claim 1 is characterized in that: the weight portion of each composition is distinguished as follows:
Herba Achilleae 10～60
Herba Artemisiae annuae 8～20
Radix Glycyrrhizae 8～20.
8. according to the said pharmaceutical composition of the arbitrary claim of claim 1 to 7, it is characterized in that: the dosage form of said compositions is: capsule, granule, pill, powder, tablet, oral liquid, syrup, gargarism, drop pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101971283A CN101829185B (en) | 2010-06-02 | 2010-06-02 | Medicinal composition for resisting influenza virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101971283A CN101829185B (en) | 2010-06-02 | 2010-06-02 | Medicinal composition for resisting influenza virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101829185A CN101829185A (en) | 2010-09-15 |
| CN101829185B true CN101829185B (en) | 2012-02-15 |
Family
ID=42713506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101971283A Expired - Fee Related CN101829185B (en) | 2010-06-02 | 2010-06-02 | Medicinal composition for resisting influenza virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101829185B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103202868B (en) * | 2013-04-02 | 2014-11-26 | 西北农林科技大学 | Composition for preventing and treating flu as well as preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1304019C (en) * | 2003-05-29 | 2007-03-14 | 斯拉甫·艾白 | Compound artemisia rupestris capsule |
| CN1583152A (en) * | 2004-06-09 | 2005-02-23 | 新疆维吾尔自治区药物研究所 | Anti-virus capsules of Jinhao |
-
2010
- 2010-06-02 CN CN2010101971283A patent/CN101829185B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101829185A (en) | 2010-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102698137B (en) | Composition with blood pressure reducing function and preparation method of same | |
| CN101129636A (en) | Medicine for treating nasal inflammation | |
| CN103800447A (en) | Ageratum-scutellaria baicalensis antipyretic granule | |
| CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN103316086B (en) | Tibetan medicine for treating influenza and preparation method thereof | |
| CN103961614A (en) | Traditional Chinese medicine composition for treating respiratory system diseases as well as preparation method and application thereof | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN105381153A (en) | Traditional Chinese medicine preparation for treating bronchitis and preparation method thereof | |
| CN103191167B (en) | Application of eupatorium Chinese | |
| CN101829185B (en) | Medicinal composition for resisting influenza virus | |
| CN102188483B (en) | Extract for treating pharyngolaryngitis and preparation method thereof | |
| CN104524273A (en) | Preparation method of Yinqiao preparation | |
| CN101904935A (en) | Chinese medicinal composition for improving immunity of organisms, tonifying middle-jiao and qi and treating canine distemper | |
| CN103623065A (en) | Medicine composition for treating influenza | |
| CN102451401A (en) | Recipe of vitamin C lonicera and forsythia | |
| CN105998840A (en) | External use ointment used for treating insect bite dermatitis and preparation method | |
| CN102836203B (en) | Traditional Chinese medicine composition for treating wind-heat type common cold as well as preparation method and application thereof | |
| CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
| CN105106601A (en) | Medicinal preparation for treating acute nasopharyngitis | |
| CN105327182A (en) | Medicine for treating child pertussis and preparation method thereof | |
| CN111281921A (en) | A Chinese medicinal composition for treating common cold, pneumonia, enteritis and nephritis | |
| CN103989931A (en) | Traditional Chinese medicine for treating infantile cough and preparation method thereof | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN102058792A (en) | Traditional Chinese medicine preparation for treatment of cold and cough | |
| CN107468885A (en) | A kind of pill medicine for treating viral respiratory infection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120215 Termination date: 20120602 |